PuSH - Publikationsserver des Helmholtz Zentrums München

Townsend, E.C.* ; Murakami, M.A.* ; Christodoulou, A.N.* ; Christie, A.L.* ; Koster, J.* ; DeSouza, T.A.* ; Morgan, E.A.* ; Kallgren, S.P.* ; Liu, H.* ; Wu, S.C.* ; Plana, O.* ; Montero, J.* ; Stevenson, K.E.* ; Rao, P.* ; Vadhi, R.* ; Andreeff, M.* ; Armand, P.* ; Ballen, K.K.* ; Barzaghi-Rinaudo, P.* ; Cahill, S.* ; Clark, R.A.* ; Cooke, V.G.* ; Davids, M.S.* ; DeAngelo, D.J.* ; Dorfman, D.M.* ; Eaton, H.* ; Ebert, B.L.* ; Etchin, J.* ; Firestone, B.* ; Fisher, D.C.* ; Freedman, A.S.* ; Galinsky, I.A.* ; Gao, H.* ; Garcia, J.S.* ; Garnache-Ottou, F.* ; Graubert, T.A.* ; Gutierrez, A.* ; Halilovic, E.* ; Harris, M.H.* ; Herbert, Z.T.* ; Horwitz, S.M.* ; Inghirami, G.* ; Intlekoffer, A.M.* ; Ito, M.* ; Izraeli, S.* ; Jacobsen, E.D.* ; Jacobson, C.A.* ; Jeay, S.* ; Jeremias, I. ; Kelliher, M.A.* ; Koch, R.* ; Konopleva, M.* ; Kopp, N.* ; Kornblau, S.M.* ; Kung, A.L.* ; Kupper, T.S.* ; LaBoeuf, N.* ; LaCasce, A.S.* ; Lees, E.* ; Li, L.S.* ; Look, A.T.* ; Murakami, M.* ; Muschen, M.* ; Neuberg, D.* ; Ng, S.Y.* ; Odejide, O.O.* ; Orkin, S.H.* ; Paquette, R.R.* ; Place, A.E.* ; Roderick, J.E.* ; Ryan, J.A.* ; Sallan, S.E.* ; Shoji, B.* ; Silverman, L.B.* ; Soiffer, R.J.* ; Steensma, D.P.* ; Stegmaier, K.* ; Stone, R.M.* ; Tamburini, J.* ; Thorner, A.R.* ; van Hummelen, P.* ; Wadleigh, M.* ; Wiesmann, M.* ; Weng, A.P.* ; Wuerthner, J.U.* ; Williams, D.A.* ; Wollison, B.M.* ; Lane, A.A.* ; Letai, A.G.* ; Bertagnolli, M.M.* ; Ritz, J.* ; Brown, M.* ; Long, H.* ; Aster, J.C.* ; Shipp, M.A.* ; Griffin, J.D.* ; Weinstock, D.M.*

The public repository of xenografts enables discovery and randomized phase II-like trials in mice.

Cancer Cell 29, 574-586 (2016)
Verlagsversion DOI PMC
Free by publisher
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Acute Lymphoblastic-leukemia; Cancer Xenografts; Tumor Xenografts; Gene-expression; Clinical-trial; Models; Heterogeneity; Inhibition; Resistance; Mechanisms
ISSN (print) / ISBN 1535-6108
e-ISSN 1878-3686
Zeitschrift Cancer Cell
Quellenangaben Band: 29, Heft: 4, Seiten: 574-586 Artikelnummer: , Supplement: ,
Verlag Cell Press
Verlagsort Cambridge, Mass.
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)